Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma [A19276]. It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where it methylates homocysteine and forms methionine and tetrahydrofolate (THF). Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773]. It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.
Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Prenate Pixie
PNV Tabs 20-1
Biopar delta-FORTE
L-Methyl MC NAC
Livita Children
Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium
Levomefolate Calcium, Pyridoxal 5-phosphate, Methylcobalamin and Schizochytrium DHA Oil
Hemax
TriStart DHA
BumP DHA
Enl
OBTREX DHA Combo Pack
Zatean-Pn Plus
WesCap-PN DHA
Chromagen
Menatrol
Tricare Prenatal 2-part Daily Prenatal Vitamin System
Obtrex One
L-Methylfolate Calcium
Quflora Pediatric
Obstetrix ONE
Floriva Plus
Hematron-AF
Zatean-Pn
Folene
Puralor
Sodium polysulthionate, 5-methyltetrahydrofolate
Quflora FE Pediatric Drops
Multi-Vit-Flor
Sulfzix
Tri-Vi-Flor
Yaz Plus
Prenate Mini
Virt-PN DHA
Indication
For the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682